Article
Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
EBioMedicine - 1 Feb 2022
Kovacech Branislav, Fialova Lubica, Filipcik Peter, Skrabana Rostislav, Zilkova Monika, Paulenka-Ivanovova Natalia, Kovac Andrej, Palova Denisa, Rolkova Gabriela Paulikova, Tomkova Katarina, Csokova Natalia Turic, Markova Karina, Skrabanova Michaela, Sinska Kristina, Basheer Neha, Majerova Petra, Hanes Jozef, Parrak Vojtech, Prcina Michal, Cehlar Ondrej, Cente Martin, Piestansky Juraj, Fresser Michal, Novak Michal, Slavikova Monika, Borsova Kristina, Cabanova Viktoria, Brejova Bronislava, Vinař Tomas, Nosek Jozef, Klempa Boris, Eyer Ludek, Hönig Vaclav, Palus Martin, Ruzek Daniel, Vyhlidalova Tereza, Strakova Petra, Mrazkova Blanka, Zudova Dagmar, Koubkova Gizela, Novosadova Vendula, Prochazka Jan, Sedlacek Radislav, Zilka Norbert, Kontsekova Eva
Abstract excerpt
BACKGROUND: The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S protein raised concern about activity of current vaccines and therapeutic antibodies. Independent studies have shown that mutant variants are partially or completely resistant against some of the therapeutic antibodies authorized for emergency use....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.